Analysts expect Infinity Pharmaceuticals Inc. (NASDAQ:INFI) to announce ($0.14) earnings per share (EPS) for the current quarter, Zacks Investment Research reports. Zero analysts have provided estimates for Infinity Pharmaceuticals’ earnings, with estimates ranging from ($0.18) to ($0.12). Infinity Pharmaceuticals also posted earnings of ($0.14) per share in the same quarter last year. The company is scheduled to report its next earnings report on Tuesday, November 6th.
On average, analysts expect that Infinity Pharmaceuticals will report full year earnings of ($0.57) per share for the current year, with EPS estimates ranging from ($0.67) to ($0.51). For the next fiscal year, analysts anticipate that the company will report earnings of ($0.50) per share, with EPS estimates ranging from ($0.81) to ($0.24). Zacks’ earnings per share calculations are an average based on a survey of sell-side research firms that cover Infinity Pharmaceuticals.
Infinity Pharmaceuticals (NASDAQ:INFI) last released its quarterly earnings data on Tuesday, August 7th. The biotechnology company reported ($0.12) EPS for the quarter, beating the Zacks’ consensus estimate of ($0.20) by $0.08.
Institutional investors and hedge funds have recently bought and sold shares of the business. Dimensional Fund Advisors LP increased its stake in shares of Infinity Pharmaceuticals by 27.0% in the 2nd quarter. Dimensional Fund Advisors LP now owns 932,370 shares of the biotechnology company’s stock valued at $1,781,000 after acquiring an additional 198,098 shares during the last quarter. Acadian Asset Management LLC increased its stake in Infinity Pharmaceuticals by 95.2% during the 2nd quarter. Acadian Asset Management LLC now owns 372,009 shares of the biotechnology company’s stock worth $711,000 after purchasing an additional 181,436 shares in the last quarter. Essex Investment Management Co. LLC increased its stake in Infinity Pharmaceuticals by 121.4% during the 3rd quarter. Essex Investment Management Co. LLC now owns 364,401 shares of the biotechnology company’s stock worth $988,000 after purchasing an additional 199,796 shares in the last quarter. GSA Capital Partners LLP increased its stake in Infinity Pharmaceuticals by 2,112.9% during the 1st quarter. GSA Capital Partners LLP now owns 302,154 shares of the biotechnology company’s stock worth $635,000 after purchasing an additional 288,500 shares in the last quarter. Finally, Wells Fargo & Company MN increased its stake in Infinity Pharmaceuticals by 83.1% during the 1st quarter. Wells Fargo & Company MN now owns 192,493 shares of the biotechnology company’s stock worth $404,000 after purchasing an additional 87,357 shares in the last quarter. Hedge funds and other institutional investors own 49.28% of the company’s stock.
Shares of NASDAQ INFI traded down $0.18 during midday trading on Friday, reaching $2.49. 8,062 shares of the stock were exchanged, compared to its average volume of 572,168. The company has a market capitalization of $154.07 million, a P/E ratio of -3.18 and a beta of 2.25. Infinity Pharmaceuticals has a twelve month low of $1.65 and a twelve month high of $2.92.
Infinity Pharmaceuticals Company Profile
Infinity Pharmaceuticals, Inc, a biopharmaceutical company, develops medicines for people with cancer in the United States. Its product candidate is IPI-549, an orally administered clinical-stage immuno-oncology product candidate that inhibits the enzyme phosphoinositide-3-kinase-gamma (PI3K-gamma), which is in Phase 1/1b clinical study.
Read More: Stock Split
For more information about research offerings from Zacks Investment Research, visit Zacks.com
Receive News & Ratings for Infinity Pharmaceuticals Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Infinity Pharmaceuticals and related companies with MarketBeat.com's FREE daily email newsletter.